{"id":"F2022L00920","name":"Statement of Principles concerning sick sinus syndrome (Balance of Probabilities) (No. 67 of 2022)","slug":"statement-of-principles-concerning-sick-sinus-syndrome-balance-of-probabilities-no-67-of-2022","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":441453,"registerId":"F2022L00920-fast-fetch-1775956740608","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning sick sinus syndrome (Balance of Probabilities) (No. 67 of 2022)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\nmeta-generator: Aspose.Words for .NET 22.10.0\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n\n\n \n\nStatement of Principles\n\nconcerning\n\nSICK SINUS SYNDROME (Balance of Probabilities)\n\n(No. 67 of 2022)\n\nThe Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(3) of the Veterans' Entitlements Act 1986.\n\n \n\nDated 24 June 2022\n\n \n\n \n\n \n\n \n\n \n\n| The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:
|\n| --- |\n|
Professor Terence Campbell AM
Chairperson
|\n\n\n \n\n \n\n\nContents\n\n1 Name\n\n2 Commencement\n\n3 Authority\n\n4 Repeal\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\n \n\n\n\n\n1 Name\n\nThis is the Statement of Principles concerning sick sinus syndrome (Balance of Probabilities) (No. 67 of 2022).\n\n2 Commencement\n\n This instrument commences on 25 July 2022.\n\n3 Authority\n\nThis instrument is made under subsection 196B(3) of the Veterans' Entitlements Act 1986.\n\n4 Repeal\n\nThe Statement of Principles concerning sick sinus syndrome No. 16 of 2014 (Federal Register of Legislation No. F2014L00024) made under subsection 196B(3) of the VEA is repealed.\n\n5 Application\n\nThis instrument applies to a claim to which section 120B of the VEA or section 339 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6 Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n(1) This Statement of Principles is about sick sinus syndrome and death from sick sinus syndrome.\n\nMeaning of sick sinus syndrome\n\n(2) For the purposes of this Statement of Principles, sick sinus syndrome:\n\n(a) means a group of cardiac arrhythmias caused by dysfunction of the sinus node, in which persistent or intermittent abnormalities of cardiac impulse formation and propagation cause an atrial rate inappropriate for physiological requirements, resulting in clinical symptoms; and\n\n(b) excludes congenital sick sinus syndrome.\n\nNote 1: Sick sinus syndrome can manifest as persistent or intermittent sinus bradycardia, sinus pause or sinus arrest, bradycardia-tachycardia syndrome, and other arrhythmias.\n\nNote 2: Symptoms of sick sinus syndrome typically include fatigue, lightheadedness, palpitations, presyncope, syncope, dyspnoea on exertion, and chest discomfort. Documented sinus node dysfunction correlates with symptoms. Symptoms are frequently intermittent with gradual progression in frequency and severity.\n\n(3) While sick sinus syndrome attracts ICD‑10‑AM code I49.5, in applying this Statement of Principles the meaning of sick sinus syndrome is that given in subsection (2).\n\n(4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.\n\nDeath from sick sinus syndrome\n\n(5) For the purposes of this Statement of Principles, sick sinus syndrome, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's sick sinus syndrome.\n\nNote: terminal event is defined in the Schedule 1 - Dictionary.\n\n8 Basis for determining the factors\n\nOn the sound medical‑scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that sick sinus syndrome and death from sick sinus syndrome can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the MRCA.\n\nNote: MRCA, relevant service and VEA are defined in the Schedule 1 - Dictionary.\n\n9 Factors that must exist\n\nAt least one of the following factors must exist before it can be said that, on the balance of probabilities, sick sinus syndrome or death from sick sinus syndrome is connected with the circumstances of a person's relevant service:\n\n(1) having atrial fibrillation or atrial flutter at the time of the clinical onset of sick sinus syndrome;\n\n(2) having hypertension at the time of the clinical onset of sick sinus syndrome;\n\n(3) having ischaemic heart disease at the time of the clinical onset of sick sinus syndrome;\n\n(4) having heart failure at the time of the clinical onset of sick sinus syndrome;\n\n(5) having rheumatic fever at the time of the clinical onset of sick sinus syndrome;\n\n(6) having pericarditis at the time of the clinical onset of sick sinus syndrome;\n\n(7) having cardiomyopathy at the time of the clinical onset of sick sinus syndrome;\n\n(8) having non-infectious myocarditis at the time of the clinical onset of sick sinus syndrome;\n\nNote 1: Non-infectious myocarditis can be acute or chronic.\n\nNote 2: Non-infectious myocarditis can be of autoimmune, infiltrative or immunological origin. Examples of causes of non-infectious myocarditis include immune checkpoint inhibitor therapy and giant cell myocarditis.\n\n(9) having viral myocarditis at the time of the clinical onset of sick sinus syndrome;\n\nNote 1: Viral myocarditis can be acute or chronic.\n\nNote 2: Examples of viral causes of myocarditis include severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human immunodeficiency virus, group B coxsackieviruses and dengue virus.\n\n(10) having a non-viral infection of the myocardium at the time of the clinical onset of sick sinus syndrome;\n\nNote 1: A non-viral infection of the myocardium can be caused by bacteria, protozoa, fungi or parasites. \n\nNote 2: Examples of non-viral infections of the myocardium include:\n\n(a) Borrelia burgdorferi (Lyme disease);\n\n(b) Cysticercus species (cysticercosis);\n\n(c) Echinococcus species (hydatid disease);\n\n(d) Toxoplasma gondii (toxoplasmosis); and\n\n(e) Trypanosoma cruzi (Chagas disease).\n\n(11) having a benign or malignant neoplasm involving the sinoatrial node before the clinical onset of sick sinus syndrome;\n\nNote: A neoplasm involving the sinoatrial node can be primary or metastatic. An example of a primary neoplasm involving the sinoatrial node is cardiac lymphoma.\n\n(12) having a non-neoplastic lesion which compresses the sinoatrial node at the time of the clinical onset of sick sinus syndrome;\n\nNote: Examples of non-neoplastic lesions which compress the sinoatrial node include cardiac tamponade and coronary artery aneurysm.\n\n(13) having hypothyroidism, including Hashimoto thyroiditis that has resulted in hypothyroidism, at the time of the clinical onset of sick sinus syndrome;\n\n(14) having a thoracic surgical procedure or an invasive cardiac procedure within the 1 year before the clinical onset of sick sinus syndrome;\n\nNote 1: Examples of thoracic surgical procedures include vascular, mediastinal, pulmonary and chest wall surgery.\n\nNote 2: Examples of invasive cardiac procedures include:\n\n(a) catheter ablation of arrhythmias;\n\n(b) open heart surgery; and\n\n(c) transcatheter aortic valve implantation.\n\n(15) having a heart transplant before the clinical onset of sick sinus syndrome;\n\n(16) having a surgical procedure involving general or regional anaesthesia within the 30 days before the clinical onset of sick sinus syndrome;\n\n(17) experiencing penetrating trauma to the heart within the 3 months before the clinical onset of sick sinus syndrome;\n\n(18) taking a drug from the specified list of drugs within the 30 days before the clinical onset of sick sinus syndrome;\n\nNote: specified list of drugs is defined in the Schedule 1 - Dictionary.\n\n(19) having atrial fibrillation or atrial flutter at the time of the clinical worsening of sick sinus syndrome;\n\n(20) having hypertension at the time of the clinical worsening of sick sinus syndrome;\n\n(21) having ischaemic heart disease at the time of the clinical worsening of sick sinus syndrome;\n\n(22) having heart failure at the time of the clinical worsening of sick sinus syndrome;\n\n(23) having rheumatic fever at the time of the clinical worsening of sick sinus syndrome;\n\n(24) having pericarditis at the time of the clinical worsening of sick sinus syndrome;\n\n(25) having cardiomyopathy at the time of the clinical worsening of sick sinus syndrome;\n\n(26) having non-infectious myocarditis at the time of the clinical worsening of sick sinus syndrome;\n\nNote 1: Non-infectious myocarditis can be acute or chronic.\n\nNote 2: Non-infectious myocarditis can be of autoimmune, infiltrative or immunological origin. Examples of causes of non-infectious myocarditis include immune checkpoint inhibitor therapy and giant cell myocarditis.\n\n(27) having viral myocarditis at the time of the clinical worsening of sick sinus syndrome;\n\nNote 1: Viral myocarditis can be acute or chronic.\n\nNote 2: Examples of viral causes of myocarditis include severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human immunodeficiency virus, group B coxsackieviruses and dengue virus.\n\n(28) having a non-viral infection of the myocardium at the time of the clinical worsening of sick sinus syndrome;\n\nNote 1: A non-viral infection of the myocardium can be caused by bacteria, protozoa, fungi or parasites. \n\nNote 2: Examples of non-viral infections of the myocardium include:\n\n(a) Borrelia burgdorferi (Lyme disease);\n\n(b) Cysticercus species (cysticercosis);\n\n(c) Echinococcus species (hydatid disease);\n\n(d) Toxoplasma gondii (toxoplasmosis); and\n\n(e) Trypanosoma cruzi (Chagas disease).\n\n(29) having a benign or malignant neoplasm involving the sinoatrial node before the clinical worsening of sick sinus syndrome;\n\nNote: A neoplasm involving the sinoatrial node can be primary or metastatic. An example of a primary neoplasm involving the sinoatrial node is cardiac lymphoma.\n\n(30) having a non-neoplastic lesion which compresses the sinoatrial node at the time of the clinical worsening of sick sinus syndrome;\n\nNote: Examples of non-neoplastic lesions which compress the sinoatrial node include cardiac tamponade and coronary artery aneurysm.\n\n(31) having hypothyroidism, including Hashimoto thyroiditis that has resulted in hypothyroidism, at the time of the clinical worsening of sick sinus syndrome;\n\n(32) having a thoracic surgical procedure or an invasive cardiac procedure within the 1 year before the clinical worsening of sick sinus syndrome;\n\nNote 1: Examples of thoracic surgical procedures include vascular, mediastinal, pulmonary and chest wall surgery.\n\nNote 2: Examples of invasive cardiac procedures include:\n\n(a) catheter ablation of arrhythmias;\n\n(b) open heart surgery; and\n\n(c) transcatheter aortic valve implantation.\n\n(33) having a heart transplant before the clinical worsening of sick sinus syndrome;\n\n(34) having a surgical procedure involving general or regional anaesthesia within the 30 days before the clinical worsening of sick sinus syndrome;\n\n(35) experiencing penetrating trauma to the heart within the 3 months before the clinical worsening of sick sinus syndrome;\n\n(36) taking a drug from the specified list of drugs within the 30 days before the clinical worsening of sick sinus syndrome;\n\nNote: specified list of drugs is defined in the Schedule 1 - Dictionary.\n\n(37) inability to obtain appropriate clinical management for sick sinus syndrome.\n\n10 Relationship to service\n\n(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2) The factors set out in subsections 9(19) to 9(37) apply only to material contribution to, or aggravation of, sick sinus syndrome where the person's sick sinus syndrome was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1) if a factor referred to in section 9 applies in relation to a person; and\n\n(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(3) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\n \n\n \n\nSchedule 1 - Dictionary \n\nNote: See Section 6\n\n1 Definitions\n\nIn this instrument:\n\n MRCA means the Military Rehabilitation and Compensation Act 2004.\n\n relevant service means:\n\n(a) eligible war service (other than operational service) under the VEA;\n\n(b) defence service (other than hazardous service and British nuclear test defence service) under the VEA; or\n\n(c) peacetime service under the MRCA.\n\nNote: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\n sick sinus syndrome—see subsection 7(2).\n\n specified list of drugs means:\n\n(a) a general or regional anaesthetic;\n\n(b) acetylcholinesterase inhibitors including donepezil, galantamine, neostigmine and rivastigmine;\n\n(c) antidepressants including amitriptyline;\n\n(d) antihypertensives including clonidine and methyldopa;\n\n(e) antipsychotic phenothiazines;\n\n(f) beta blockers;\n\n(g) cardiac glycosides including digoxin;\n\n(h) class 1A, class 1C or class III anti-arrhythmic agents;\n\n(i) lacosamide;\n\n(j) lidocaine;\n\n(k) lithium; or\n\n(l) non-dihydropyridine calcium channel blockers including diltiazem and verapamil.\n\n terminal event means the proximate or ultimate cause of death and includes the following:\n\n(a) pneumonia;\n\n(b) respiratory failure;\n\n(c) cardiac arrest;\n\n(d) circulatory failure; or\n\n(e) cessation of brain function.\n\n VEA means the Veterans' Entitlements Act 1986.\n\n \n\n \n","sortOrder":0}],"analysis":{"kimi_summary":{"content_quality":"ok","complexity_score":4,"scope_assessment":{"changed":false,"description":"This instrument maintains the established scope of Repatriation Medical Authority Statements of Principles. It replaces the 2014 version (No. 16 of 2014) with updated medical evidence but does not expand beyond the traditional purpose of establishing service connection criteria for specific conditions. The structure follows the standard template: definition, factors for onset, factors for worsening, relationship to service, and dictionary. The inclusion of contemporary examples (SARS-CoV-2, immune checkpoint inhibitors) reflects updated medical knowledge rather than scope creep."},"complexity_factors":["37 distinct factual factors with specific temporal requirements (e.g., 'within 30 days', 'within 1 year', 'within 3 months')","Parallel structure requiring near-duplication of factors for 'clinical onset' (factors 1-18) and 'clinical worsening' (factors 19-36)","Cross-referencing to other Statements of Principles for nested conditions (section 11)","Defined terms in Schedule 1 including a detailed 12-category drug list with examples","Dual legislative framework application (VEA and MRCA with different service definitions)","Specific exclusion of congenital cases and inclusion of death from terminal events","ICD-10-AM coding reference with specific edition requirements"],"plain_english_summary":"This rulebook sets the medical criteria used to decide whether Australian veterans and current or former defence force members can establish, on the balance of probabilities, that their sick sinus syndrome is connected to military service for claims under the VEA or MRCA. \n\nBy updating earlier guidance, it defines the required medical evidence and service-related links — a determination that directly affects access to compensation, treatment and ongoing support for affected personnel."},"flash_summary":{"complexity_score":5,"scope_assessment":{"changed":true,"description":"This 2022 Statement replaces the 2014 Statement (section 4) and appears to broaden and update the scope in several concrete ways. Notable expansions include: (a) explicit example references to newer or more specific causes — e.g. SARS‑CoV‑2 as an example of a viral cause of myocarditis and immune checkpoint inhibitor therapy as an example of non‑infectious myocarditis (section 9 notes); (b) an explicit factor for \"inability to obtain appropriate clinical management\" (section 9(37)); and (c) a detailed and relatively comprehensive specified list of drugs (Schedule 1) and precise look‑back windows for procedures, anaesthesia, trauma and drug exposure (section 9). These additions increase the range of factual scenarios that could meet the \"balance of probabilities\" link to service, thereby widening the practical scope of compensable cases compared with a simpler, earlier instrument that this replaces."},"complexity_factors":["Replacement of an earlier Statement of Principles and cross-reference to VEA and MRCA (section 4, 5)","37 discrete factors listed in section 9 (onset and worsening sets largely mirror each other)","Multiple defined terms in Schedule 1 (eg relevant service, terminal event, specified list of drugs, sick sinus syndrome)","Several look‑back/temporal windows with different lengths (1 year, 30 days, 3 months) (section 9)","Cross‑reference mechanism to other Statements of Principles when factors overlap (section 11)","Clinical‑medical concepts that need specialist interpretation (eg clinical onset, clinical worsening, non‑infectious vs viral myocarditis, neoplasms of the sinoatrial node)","A specified drug list with heterogeneous agents requiring pharmacological judgment (Schedule 1)","Inclusion of both onset and worsening criteria and an additional open factor (inability to obtain appropriate clinical management) that is fact‑sensitive (section 9(37))","References to ICD‑10‑AM coding and external medical classifications (section 7(3)–(4))"],"plain_english_summary":"**What this instrument does (mechanically)\n\n- Replaces the previous Statement of Principles for sick sinus syndrome (No. 16 of 2014) with a new Statement of Principles numbered No. 67 of 2022 (section 4). The new instrument commenced on 25 July 2022 (section 2). \n- Applies to claims under the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA) where the specified claim provisions apply (section 5). \n- Defines what the Repatriation Medical Authority (RMA) means by \"sick sinus syndrome\" for claims purposes, explicitly excluding congenital sick sinus syndrome and noting the usual symptoms and ICD‑10‑AM code (section 7). \n- Treats death as included where the terminal event was contributed to by sick sinus syndrome (section 7(5) and the dictionary definition of \"terminal event\").\n- Lists the specific medical and temporal factors that must exist (at least one) for a decision‑maker to find, on the balance of probabilities, that a veteran's sick sinus syndrome (or death from it) is connected to their relevant service (section 9). These factors cover pre‑existing or concurrent cardiac conditions (eg atrial fibrillation, hypertension, ischaemic heart disease, myocarditis, cardiomyopathy), surgical or traumatic events and defined time windows (eg thoracic or invasive cardiac procedure within 1 year; surgery with anaesthesia within 30 days; penetrating trauma within 3 months), exposure to a specified list of drugs within 30 days, inability to obtain appropriate clinical management, and more (section 9 and Schedule 1).\n- Requires any factor relied on to be related to the person's \"relevant service\" as defined in the instrument (section 10). Some factors only apply when a condition was suffered or contracted before or during, but not as a result of, relevant service (section 10(2)).\n- Provides that, if a listed factor refers to an injury or disease that itself has its own Statement of Principles, that other Statement of Principles applies in accordance with its own terms (section 11).\n\nOfficial rationale (what the RMA says it is doing)\n\n- The RMA states that, based on available medical‑scientific evidence, it is more probable than not that sick sinus syndrome and death from it can be related to relevant service (section 8). The Statement thus identifies the medical and temporal circumstances in which a connection to service may be accepted for claims purposes.\n\nHow this matters in practice — who decides, who pays, what changes behaviour\n\n- Who decides: claims decision‑makers and medical assessors use this Statement of Principles as the medical standard to decide whether sick sinus syndrome is connected with a person's relevant service for VEA/MRCA claims (sections 5, 6, 9, 11). The RMA issues the Statement but does not itself grant claims—its role is to set the medical criteria.\n- Who pays: if a decision‑maker accepts connection to service using this Statement, the legal entitlements (pensions, treatment, compensation) under the VEA or MRCA would be paid by the Commonwealth according to those Acts.\n- Behavioural and evidentiary effects: claimants (and their clinicians) will focus on documenting the presence of at least one listed factor at the relevant time (onset or worsening), and on evidence that links that factor to the person's relevant service. Decision‑makers will assess temporal links (eg timing windows for procedures or drug exposure) and whether clinical management was \"appropriate\" when inability to obtain care is relied on (sections 9, 10).\n\nPractical implications, costs and trade‑offs (testing the RMA's purpose claim)\n\n- Benefit concentration vs cost diffusion: expanding or clarifying accepted causal links makes it easier for individual veterans with the listed factors to succeed in claims; the fiscal cost of successful claims is borne by the Commonwealth (sections 9, Schedule 1). The instrument itself does not set monetary amounts, but broadening accepted medical links can increase program liability.\n- Administrative and evidentiary burden: decision‑makers must apply multiple temporal rules and medical categories (eg onset vs worsening; different look‑back periods for procedures, anaesthesia, trauma and drugs). Claimants must produce medical records showing timing and diagnosis (sections 9, 10). This increases complexity for claims assessment and may lengthen adjudication time.\n- Medical uncertainty and need for specialist evidence: many listed factors (eg myocarditis, cardiomyopathy, neoplasms of the sinoatrial node, drug effects) require specialist cardiological or infectious disease evidence to establish presence and timing. The instrument expects clinical proof rather than conjecture (section 9 and Schedule 1 definitions). \n- Overlap and cross‑reference to other Statements of Principles: where a factor is itself the subject of another Statement of Principles, that other instrument governs how the factor is treated (section 11). This can reduce duplicate analysis but requires cross‑checking multiple Statements of Principles.\n- Discretion and interpretation risk: terms such as \"clinical onset\", \"clinical worsening\", \"inability to obtain appropriate clinical management\", and some time windows invite interpretive judgements by medical assessors. Different assessments of what counts as \"at the time of\" an event or what constitutes \"appropriate\" care could produce inconsistent outcomes (sections 7, 9, 37, Schedule 1). \n- Effects on private choice and providers: clinicians documenting the listed conditions and timing will materially influence claim outcomes. There is no direct regulatory effect on private medical practice, but clinicians' records become evidence that affects entitlements.\n\nConcrete items to note in application (section citations)\n\n- The instrument explicitly excludes congenital sick sinus syndrome (section 7(2)(b)).\n- Death is included if the terminal event was contributed to by sick sinus syndrome; \"terminal event\" is defined in the dictionary (section 7(5) and Schedule 1). \n- Time windows: invasive cardiac or thoracic surgery within 1 year (9(14), 9(32)); general or regional anaesthesia within 30 days (9(16), 9(34)); penetrating cardiac trauma within 3 months (9(17), 9(35)); drugs in the specified list within 30 days (9(18), 9(36) and Schedule 1).\n- Examples added in notes: non‑infectious myocarditis examples include immune checkpoint inhibitor therapy and giant cell myocarditis (9(8) note); viral myocarditis example includes SARS‑CoV‑2 (9(9) note).\n\nBottom line: The instrument is a rules‑based medical guide used by claims decision‑makers. It replaces the previous Statement of Principles, defines sick sinus syndrome for claims purposes, enumerates specific medical and temporal factors that establish a connection to service on the balance of probabilities, and creates identifiable evidentiary and administrative consequences for claimants, clinicians and assessors (sections 2–11, Schedule 1)."},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-sick-sinus-syndrome-balance-of-probabilities-no-67-of-2022","history":"/api/acts/statement-of-principles-concerning-sick-sinus-syndrome-balance-of-probabilities-no-67-of-2022/history","analysis":"/api/acts/statement-of-principles-concerning-sick-sinus-syndrome-balance-of-probabilities-no-67-of-2022/analysis","conflicts":"/api/acts/statement-of-principles-concerning-sick-sinus-syndrome-balance-of-probabilities-no-67-of-2022/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-sick-sinus-syndrome-balance-of-probabilities-no-67-of-2022/important-cases","documents":"/api/acts/statement-of-principles-concerning-sick-sinus-syndrome-balance-of-probabilities-no-67-of-2022/documents"}}